Legal notice

Identification data

Identification data in accordance with Act 34/2002 of 11th July, on Information Society and E-commerce Services:

ABILITY PHARMACEUTICALS, SL ("ABILITYPHARMA"), proprietor of this web site, has its registered address at Edifici Eureka, Campus de la UAB, 08193 Bellaterra (Barcelona), Catalonia, Spain, VAT number B65217671 and is registered at the Mercantile Register of Barcelona, Book 41,611, Sheet 122, Page B393915/1; having the following email address for contact purposes

Terms of Use

Access to, and use of, this website (hereinafter “the Website”) is subject to the conditions detailed below and to the legislation in force.
By accessing and exploring the Website content, the user accepts, without limitation, these terms of use and acknowledges that any other agreement with ABILITYPHARMA is superseded and of no force or effect.

ABILITYPHARMA reserves the right, at any time and without prior notice, to alter and update the information contained in its Website, as well as to change its configuration and presentation and its access and conditions of use. The user is automatically bound by the terms of use in force at the time they access the Website, for this reason it is important to periodically read this Legal Warning.

The user accepts that use of the Website, its services and content is carried out at their own responsibility. The user additionally undertakes not to use the Website for illicit purposes or contrary to the content expressed in this Legal Warning or any other legislation that may be applicable.

Availability of and Accessibility to the Website

The user of the Website, by accessing it, hereby agrees to use it in full compliance with the applicable legislation in force and will respond, for any loss and/or damage that may arise due to incompliance from said obligation, to ABILITYPHARMA and/or third parties.

ABILITYPHARMA will not be liable for damages arising from the use of the present Website, nor for any action carried out based on the information provided in it.

ABILITYPHARMA is not liable for any security errors or disconnections that may occur nor for any damage caused to the user’s computer system (hardware and software), or files and documents stored there, as a result of a computer virus in the user’s computer when accessing the services and contents of the Website, nor for the malfunction of the browser or from the use of any backdated versions of the browser.

Responsibility for links and hyperlinks

In order to help the user encounter further information or services of interest, the Website may include direct links to other internet pages. These target websites have not been reviewed by ABILITYPHARMA and are maintained by third parties over whom ABILITYPHARMA has no control.

Access to such websites by the user does not imply that ABILITYPHARMA recommends or approves of the contents contained therein. ABILITYPHARMA expressly denies any responsibility over the correct working of these links, their contents or the exactness of the information they contain, the quality of any of the products or services they offer or advertise or for the results obtained through these links. Likewise ABILITYPHARMA expressly denies any responsibility for any damages suffered by the user in virtue of the information encountered in these target websites.

Website Contents

The Website contents are for information purposes only; they are insufficient for the user to be able to make decisions. The user must bear in mind that the contents of the Website relating to products or services offered by ABILITYPHARMA or any other company belonging to ABILITYPHARMA may not be updated.

The Website may contain information about products belonging to ABILITYPHARMA and/or other companies belonging to ABILITYPHARMA that may, or may not, be available in a determined country. In some cases, such products may have been authorized for sale by a government organization with different indications or restrictions depending on the country. Different countries have their own laws, regulations and specific medical practices which govern the publication of information relating to medical checks and products on the Internet. The content of this Website should not under any circumstance be interpreted as a request, promotion or indication for any product that has not been previously authorized by the laws and regulations in force in the country where the user resides.

The Website may contain information regarding medical or healthcare matters. The information here-contained does not aim to replace the advice of a doctor or the counseling of any other healthcare professional. The user must not utilize the information contained on the Website to diagnose an illness or health problem, but should always consult such issues with a qualified physician.

Personal Data

In accordance with Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Personal Data, the user hereby consents to ABILITYPHARMA processing their personal data.

The only personal data that ABILITYPHARMA will have access to, are those provided voluntarily by the user using the forms destined for this purpose.

In each case the user will be informed of the purpose for which their personal data will be used. ABILITYPHARMA will not give the personal data provided by the user over the Website to any third parties unless (i) the user agrees to this or (ii) it is essentials in order to comply with legal requirements.

In accordance with the legislation in force, ABILITYPHARMA is committed to its obligation to maintain secret any personal data and to its duty to maintain confidentiality. To this effect ABILITYPHARMA has adopted all the necessary technical and organizational measures to maintain the level of security required in view of the personal data processed. ABILITYPHARMA also has the necessary mechanisms to avoid, as much as possible, unauthorized access and illicit removal, modification or loss of data.

To exercise the rights of access, cancellation, rectification, opposition, deletion, portability and limitation of treatment, the user may give written notice to ABILITYPHARMA at the following mailing address or at our e-mail address:

Edifici Eureka, Campus de la UAB
08193 Bellaterra (Barcelona)
Catalonia – Spain

“Cookie” files

ABILITYPHARMA uses cookie technology when a user enters the Website. Our cookies are associated solely with an anonymous user and his/her computer. These cookies do not provide references that allow the full name of the user to be deduced. However, we hereby inform that the user may prevent the generation of cookies by selecting the appropriate option in their Internet browser.


ABILITYPHARMA does not approve the practice of “spamming”. This term means the massive and repeated dispatch of unsolicited e-mails, normally of commercial character, to persons with whom the sender has not maintained any previous contact, or who have expressed their desire not to receive such messages.

If ABILITYPHARMA considers that certain information may be of interest to you, the right is reserved to provide this information to you by e-mail, with your prior consent while offering you the opportunity to exclude yourself from this service.

Rights of Intellectual and/or Industrial Property

All of the contents on the Website are protected by intellectual property rights. This content includes but is not limited to, the graphic design, source code, photographs, logos, trademarks, videos, publications and text content and other elements that appear on the Website. The user hereby recognizes that the reproduction, distribution, sale, transformation and in general any other form of exploitation, by any means, of all or part of the contents of this Website will constitute a breach of the intellectual property and/or industrial rights of ABILITYPHARMA or the title holder of the same.

Trademarks or any other type of distinctive signs contained in the Website are likewise protected by this legislation.

In no event will the user be able to modify or use the aforementioned intellectual or industrial property in such a way that its disclosure causes damages to ABILITYPHARMA . ABILITYPHARMA will claim compensation for the losses and damages derived from the illegal use of their intellectual property by third parties.

ABILITYPHARMA does not grant any license or authorization of use of any kind on its industrial and/or intellectual property or on any other property or right related to the Website, the services or the content.

Legislation and applicable jurisdiction

This legal warning will be governed by and interpreted in accordance with the laws of Spain.

Any controversy, claim or dispute regarding the interpretation, execution and/or resolution of this Legal Warning will be submitted to the courts and tribunals of the city of Barcelona.



Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police